Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

* Voluntarily understand and sign the informed consent form for this study.
* Age ≥ 18 years, male or female.
* Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition).
* ECOG performance status of 0-2.
* No prior treatment for esophageal squamous cell carcinoma.
* Life expectancy ≥ 3 months.
* Adequate function of major organs within 7 days before the first treatment (use of any blood components or cell growth factors within 14 days before enrollment is not permitted):Hemoglobin ≥ 90 g/L; White blood cell count ≥ 3.5 × 10\^9/L; Absolute neutrophil count ≥ 1.5 × 10\^9/L; Platelets ≥ 80 × 10\^9/L; AST and ALT ≤ 2.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL/min); Left ventricular ejection fraction (LVEF) ≥ 50%.
* Fertile patients must agree to use reliable contraceptive methods with their partner during the trial and for at least 180 days after the last dose.

Exclusion Criteria:

* Inability to comply with the study protocol or study procedures.
* Presence of supraclavicular lymph node metastasis.
* Obvious tumor invasion of organs adjacent to the esophageal lesion.
* Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment.
* Allergy or known hypersensitivity to the study drugs or their excipients.
* Anticipated need for systemic corticosteroids or other immunosuppressive therapy during the study treatment period.
* Active autoimmune disease requiring systemic treatment, or a history of autoimmune disease.
* Positive HIV test; positive hepatitis B surface antigen with HBV-DNA \> upper limit of normal; active hepatitis C virus (HCV) infection.
* History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months before the first study drug administration; known severe varices on endoscopy within 3 months before the first study drug administration.
* Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia that might interfere with the assessment and management of immune-related pulmonary toxicity.
* Evidence of a significant bleeding tendency or other major coagulation disorders.
* Severe cardiovascular or cerebrovascular disease.
* Other malignancies within 5 years before enrollment, except for radically resected basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
* History of allogeneic bone marrow transplantation or organ transplantation.
* Patients considered by the investigator to be unsuitable for participation in this study.